To the full analysis
Gyre Therapeutics stock: growth
GYREGyre Therapeutics reported $116.59M in revenue for fiscal 2025, up 10.2% on the prior year, up 41% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.9%
per year from 2006 to 2025, per share −23.5%
Earnings (Annual rate)
4.7%
per year from 2006 to 2025
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 41.0% | 52.2% | 7.9% |
| Revenue per share | 3.6% | −14.0% | −23.5% |
| Earnings | no data | no data | 4.7% |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $27.54M | $2.1M | −$10.97M |
| 2007 | $11.58M | −$28.07M | $19.89M |
| 2008 | $20.09M | −$25.66M | −$30.31M |
| 2009 | $25.06M | −$39.4M | −$24.47M |
| 2010 | $85.71M | $10.9M | $134.99M |
| 2011 | $97.64M | −$8.53M | −$85.15M |
| 2012 | $57.86M | −$7M | −$64.57M |
| 2013 | $3.63M | −$46.71M | −$40.7M |
| 2014 | $1.81M | −$32.62M | −$34.49M |
| 2015 | $1.75M | −$14.76M | −$19.39M |
| 2016 | $399K | −$16.95M | −$18.94M |
| 2017 | $1.02M | −$21.56M | −$19.96M |
| 2018 | $6K | −$30.06M | −$28.93M |
| 2019 | $0 | −$55.18M | −$43.68M |
| 2020 | $20.95M | −$55.54M | −$55.32M |
| 2021 | $7.34M | −$87.93M | −$84.59M |
| 2022 | $102.29M | $2.3M | $5.68M |
| 2023 | $113.45M | −$92.93M | $17.31M |
| 2024 | $105.76M | $12.09M | −$6.77M |
| 2025 | $116.59M | $5.03M | −$180K |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.